MedTrace Logo

Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue

NCT02996916 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-12-20

No results posted yet for this study

Summary

Hypertension is a leading risk factor for morbidity and mortality worldwide. The brain is a major target of the damaging effects of hypertension. Hypertension has been recognized as the leading cause of dementia as well as the most important risk factor for stroke and vascular cognitive impairment. Although glucose is the principal cerebral energy source, impact of hypertensive treatment on cerebral glucose metabolism is poorly understood.

Conditions

  • Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension

Interventions

DRUG

Olmesartan

10-40mg daily

DRUG

Amlodipine

2.5-10mg daily

Sponsors & Collaborators

  • Kurume University

    lead OTHER

Principal Investigators

  • Nobuhiro Tahara, MD, PhD · Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-12-31
Completion
2020-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02996916 on ClinicalTrials.gov